Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women

Journal of Bone and Mineral Research

Volumn 20, Issue 10, 2005, Pages 1837-1844

  Bonadonna, Stefania ^a   Mazziotti, Gherardo ^a   Nuzzo, Monica ^a   Bianchi, Antonio ^b   Fusco, Alessandra ^b   De Marinis, Laura ^b   Giustina, Andrea ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Acromegaly; Bone metabolism; Fracture; Growth hormone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; DEOXYPYRIDINOLINE; GROWTH HORMONE; PARATHYROID HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGE; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; MORPHOMETRICS; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; SPINE RADIOGRAPHY; VERTEBRA BODY; VERTEBRA FRACTURE;

ACROMEGALY; ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SPINAL INJURIES; SPINE;

EID: 25444517599     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050603     Document Type: Article

References (54)

1. Raisz LG 1988 Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 318:818-828.
2. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797.
3. Corpas E, Harman SM, Blackman MR 1993 Human growth hormone and aging. Endocr Rev 14:20-39.
4. Geusens PP, Boonen S 2002 Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 58(Suppl 3):49-55.
5. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database 2001 The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16:398-405.
6. Chiodini I, Trischitta V, Carnevale V, Liuzzi A, Scillitani A 2001 Bone mineral density in acromegaly: Does growth hormone excess protect against osteoporosis. J Endocrinol Invest 24:288-291.
7. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S, The Pituitary Society and the European Neuroendocrine Association 2003 Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247.
8. Aloja JF, Roginsky MS, Jowsey J, Dombrowski CS, Shukla KK, Cohn SH 1972 Skeletal metabolism and body composition in acromegaly. J Clin Endocrinol Metab 35:543-551.
9. Halse J, Melsen F, Mosekilde L 1981 Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol 97:18-22.
10. Halse J, Gordeladze JO 1981 Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects. Acta Endocrinol 96:451-457.
11. de la Piedra C, Larranaga J, Castro N, Horcajada C, Rapado A, Herrera Pombo JL, Carbo E 1988 Correlation among osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int 43:44-45.
12. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL1982 Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 69:1302-1309.
13. Hubush P, Kotzmann H, Svoboda T, Kainberger FM, Bankier A, Seidl G1993 Bone density of the lumbar spine and femur in acromegaly. Radiologe 33:457-461.
14. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H, Chihara K 2001 Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol 55:175-181.
15. Diamond T, Nery L, Posen S 1989 Spinal and peripheral bone mineral densities in acromegaly: The effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567-573.
16. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR 1993 Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 76:1452-1457.
17. Ho PJ, Fig LM, Barkan AL, Shapiro B 1992 Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 33:1608-1612.
18. Kotzmann H, Bernecker P, Hubsch P, Pietschmann P, Woloszczuk W, Svoboda T, Geyer G, Luger A 1993 Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459-465.
19. Kayath MJ, Vieira JGH 1997 Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 7:226-230.
20. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP 1998 Gonadal status in an important determinant of bone density in acromegaly. Clin Endocrinol 48:59-65.
21. Scillitani A, Battista C, Chiodini I, Carnevale V, Fusilli S, Ciccarelli E, Terzolo M, Oppizzi G, Arosio M, Gasperi M, Arnaldi G, Colao A, Baldelli R, Ghiggi MR, Gaia D, Di Somma C, Trischitta V, Liuzzi A 2003 Bone mineral density in acromegaly: The effect of gender, disease activity and gonadal status. Clin Endocrinol 58:725-731.
22. Scillitani A, Chiodini I, Carnevale V, Giannatempo GM, Frusciante V, Villella M, Pileri M, Guglielmi G, Di Giorgio A, Modoni S, Fusilli S, Di Cerbo A, Liuzzi A 1997 Skeletal involvement in female acromegalic subjects: The effects of growth hormone excess in amenorrheal and mestruating patients. J Bone Miner Res 12:1729-1736.
23. Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endoc Rev 19:55-79.
24. Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C 1996 Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 24:377-382.
25. Ueland T, Ebbesen EN, Thomsen JS, Mosekilde L, Brixen K, Flyvbjerg A, Bollerslev J 2002 Decreased trabecular bone biochemical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 32:122-128.
26. Lowenthal MN, Galinsky D, Fried V, Castel H, Shany S, Gazit D 1990 Acromegaly and proximal femoral fracture in an aged person: Bone histomorphometry, vitamin D metabolities and parathormone. Isr J Med Sci 26:280-283.
27. Vestergaard P, Mosekilde L 2004 Fracture risk is decreased in acromegaly-a potential beneficial effect of growth hormone. Osteoporos Int 15:155-159.
28. Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK 2003 Recognizing and reporting osteoporotic vertebral fractures. Eur Spine J 12(Suppl 2):S104-S112.
29. Lindsay R, Pack S, Li Z 2005 Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16:306-312.
30. Reeve J, Lunt M, Felsenberg D, Silman AJ, Scheidt-Nave C, Poor G, Gennari C, Weber K, Lorenc R, Masaryk P, Cannata JB, Dequeker J, Reid DM, Pols HA, Benevolenskaya LI, Stepan JJ, Miazgowski T, Bhalla A, Bruges Armas J, Eastell R, Lopes-Vaz A, Lyritis G, Jajic I, Woolf AD, Banzer D, Reisinger W, Todd CJ, Felsch B, Havelka S, Hoszowski K, Janott J, Johnell O, Raspe HH, Yershova OB, Kanis JA, Armbrecht G, Finn JD, Gowin W, O'Neill TW, European Prospective Osteoporosis Study Group 2003 Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: The European Prospective Osteoporosis Study. J Bone Miner Res 18:1664-1673.
31. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529.
32. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058.
33. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D 1997 Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390-406.
34. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996.
35. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Masaryk P, Pols HA, Poor G, Reid DM, Scheidt-Nave C, Weber K, Varlow J, Kanis JA, O'Neill TW, Silman AJ 1997 Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: The EVOS Study. J Bone Miner Res 12:1883-1894.
36. Osman AA-H, Bassiouni H, Koutri R, Nijs J, Geusens P, Dequeker J 1994 Aging of the thoracic spine: Distinction between wedging in osteoarthritis and fracture in osteoporosis-a cross-sectional and longitudinal study. Bone 15:437-442.
37. Manelli F, Carpinteri R, Bossoni S, Burattin A, Bonadonna S, Agabiti Rosei E, Giustina A 2002 Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res 30:174-183.
38. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F 2004 Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: A seven-year follow-up study. Clin Endocrinol 60:568-575.
39. Giustina A, Bussi AR, Jacobello C, Wehrenberg WB 1995 Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80:122-129.
40. Slootweg M, Swolin D, Netelenbos J, Isaksson O, Ohlsson C 1997 Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cells and human osteoblast-like cells. J Endocrinol 155:159-164.
41. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA 2004 Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34:195-202.
42. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177.
43. Cefalu CA 2004 Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 20:341-349.
44. Olesik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P 2000 Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368-1375.
45. Parfitt AM 1992 Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13(Suppl 2):S41-S47.
46. Bolanowski M, Jedrzejuk D, Milewicz A, Arkowska A 2002 Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int 13:303-308.
47. Canalis E, Bilezikian JP, Angeli A, Giustina A 2004 Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593-598.
48. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
49. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR 2000 Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 160:77-85.
50. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study 2001 The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: Results from the multiple outcomes of raloxifene evaluation study. Arthritis Rheum 44:2611-2619.
51. O'Neill TW, Cockerffl W, Matthis C, Raspe HH, Lunt M, Cooper C, Banzer D, Cannata JB, Naves M, Felsch B, Felsenberg D, Janott J, Johnell O, Kanis JA, Kragl G, Lopes Vaz A, Lyritis G, Masaryk P, Poor G, Reid DM, Reisinger W, Scheidt-Nave C, Stepan JJ, Todd CJ, Woolf AD, Reeve J, Silman AJ 2004 Back pain, disability, and radiographic vertebral fracture in European women: A prospective study. Osteoporos Int 15:760-765.
52. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E 2003 Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 18:1254-1260.
53. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426.
54. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617.